Lead Product(s): Rusalatide Acetate
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TP508
Highest Development Status: Undisclosed Product Type: Peptide
Deal Size: $10.4 million Upfront Cash: Undisclosed
Deal Type: Funding December 01, 2020
Chrysalis will conduct safety studies and additional options required to achieve Emergency Use Authorization and Animal Rule approval for TP508 as a medicinal treatment for acute and delayed effects of ionizing radiation exposure.
Lead Product(s): Blood cell therapy
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Agreement October 02, 2020
iBio will manufacture 10 proteins to be tested in the production of Safi’s cell therapies as part of the first Statement of Work. Safi will have the option to designate certain proteins as proprietary to their bioprocess, but iBio will have rights to market all other products.